Related references
Note: Only part of the references are listed.Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis
David Choi et al.
ANNALS OF PHARMACOTHERAPY (2022)
Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint
Sushrut Jangi et al.
JOURNAL OF CROHNS & COLITIS (2021)
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
Nicole L. Jarvi et al.
BIODRUGS (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2021)
Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials
Marjolijn Duijvestein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis
Rish K. Pai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Brian G. Feagan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
Sarah Harris et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
Maria T. Abreu et al.
GASTROENTEROLOGY (2020)
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects
Andreas Sturm et al.
JOURNAL OF CROHNS & COLITIS (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease
Qingdong Guan
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data
Brian Feagan et al.
INFLAMMATORY BOWEL DISEASES (2018)
Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diary
Peter D. R. Higgins et al.
JOURNAL OF PATIENT-REPORTED OUTCOMES (2018)
Development and validation of a histological index for UC
Mahmoud H. Mosli et al.
GUT (2017)
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
Jonathan Q. Tran et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases
Sinead O'Sullivan et al.
NEUROPHARMACOLOGY (2017)
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Burhan Z. Chaudhry et al.
NEUROTHERAPEUTICS (2017)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Standardisation of Study Protocols - Pros and Cons
Geert D'Haens
JOURNAL OF CROHNS & COLITIS (2016)
Central Endoscopy Reading in Inflammatory Bowel Diseases
Julian Panes et al.
JOURNAL OF CROHNS & COLITIS (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
Adnan M. Subei et al.
CNS DRUGS (2015)
Systematic review: Histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative
R. V. Bryant et al.
JOURNAL OF CROHNS & COLITIS (2014)
Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab
Harris Ahmad et al.
GASTROENTEROLOGY REPORT (2014)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Finding a way out: lymphocyte egress from lymphoid organs
Susan R. Schwab et al.
NATURE IMMUNOLOGY (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Share Paper
